Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3760984 A
Publication typeGrant
Publication date25 Sep 1973
Filing date29 Sep 1971
Priority date29 Sep 1971
Publication numberUS 3760984 A, US 3760984A, US-A-3760984, US3760984 A, US3760984A
InventorsF Theeuwes
Original AssigneeAlza Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Osmotically powered agent dispensing device with filling means
US 3760984 A
Abstract
A device is disclosed comprised of a wall formed of a material collapsable in response to mechanical force and surrounding a closed compartment for containing an agent, a dispensing passageway communicates with the compartment and the exterior of the device for dispensing agent therefrom, a filling passageway communicates with the exterior of the device and the compartment for filling the device, a layer of an osmotically effective solute is deposited on the collapsable wall's outer surface, said solute capable of exhibiting an osmotic pressure gradient against an external fluid and increasing its volume as fluid diffuses by osmosis into the solute, an outer wall surrounding the layer of solute formed of a material having shape retaining properties, permeable to the fluid and substantially impermeable to solute, and wherein the filling passageway houses a material penetrable to a means for filling the compartment which material self closes on removal of the means to maintain the compartment in closed condition for subsequent collapsing thereof in response to mechanical or hydrostatic force generated by osmotic pressure arising in the solute layer, as fluid diffuses therein to increase its volume and generate forces that are exerted between the collapsable wall of the agent containing chamber and the more rigid outer semi-permeable wall, which collapsing force in turn dispenses an agent through the dispensing passageway when the compartment is charged with drug and the device is positioned in the environment of use.
Images(3)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent 91 Theeuwes [451 Sept. 25, 1973 OSMOTICALLY POWERED AGENT DISPENSING DEVICE WITH FILLING MEANS Felix Theeuwes, Los Altos, Calif.

[52] US. Cl. 222/95, 128/260, 222/386.5,

222/389 [51] Int. Cl B65d 35/28 [58] Field of Search 222/94, 95, 190,

ZZZ/386.5, 389, 394; 129/213, 214 R, 218 R, 218 A, 260, 272; l41/3, 30

[56] References Cited UNITED STATES PATENTS 3,604,417 9/l97l Stolzeaberg 128/260 X OTHER PUBLICATIONS Australian Journal Experimental Biology (1955), 33, pp. 415-420.

Primary ExaminerRobert B. Reeves Assistant Examiner- -Larry Martin Att0meyPaul L. Sabatine et al.

[57] ABSTRACT A device is disclosed comprised of a wall formed of a material collapsable in response to mechanical force and surrounding a closed compartment for containing an agent, a dispensing passageway communicates with the compartment and the exterior of the device for dispensing agent therefrom, a filling passageway communicates with the exterior of the device and the compartment for filling the device, a layer of an osmotically effective solute is despoited on the collapsable walls outer surface, said solute capable of exhibiting an osmotic pressure gradient against an external fluid and increasing its volume as fluid diffuses by osmosis into the solute, an outer wall surrounding the layer of solute formed of a material having shape retaining properties, permeable to the fluid and substantially impermeable to solute, and wherein the filling passageway houses a material penetrable to a means for filling the compartment which material self closes on removal of the means to maintain the compartment in closed condition for subsequent collapsing thereof in response to mechanical or hydrostatic force generated by osmotic pressure arising in the solute layer, as fluid diffuses therein to increase its volume and generate forces that are exerted between the collapsable wall of the agent containing chamber and the more rigid outer semipermeable wall, which collapsing force in turn dispenses an agent through the dispensing passageway when the compartment is charged with drug and the device is positioned in the environment of use.

5 Claims, 7 Drawing Figures OSMOTICALLY POWERED AGENT DISPENSING DEVICE WITH FILLING MEANS AREA OF THE INVENTION This invention pertains to both a novel and useful device for dispensing a useful agent. More particularly, the invention relates to a dispensing device for the controlled and continuous dispensing of an agent over a prolonged period of time to produce a desired result. Specifically, the invention concerns an osmotic dispenser manufactured with a minimum number of com-' ponents wherein one of the components is a filling port with a means for self-closing the port to maintain the sterility and operability of the device after the device is charged with agent.

BACKGROUND OF THE INVENTION Osmotic dispensing devices for the delivery of active agent are well known to the prior art. These devices are of assorted designs and generally have a plurality of similar structural components. For example, the devices usually have anexternal wall or housing for containing an internal collapsable chamber for containing an agent. The chamber in the device is surrounded by an osmotically effective solute that is capable of exhibiting a pressure gradient against an extem'al fluid and increasing its volume as external fluid diffuses into the solute to generate a force that is exerted against-the chamber causing it to collapse. As the chamber collapses, it ejects agent through a passageway that lead to the exterior of the device.

While these osmotic devices are useful for dispensing agent, they have certain disadvantages that restrict or tend to defeat their use for many applications. For example, the presently available devices are prefilled with a drug which often looses its sterility prior to use of the drug. Also, some drugs have a short shelf life and these drugs tend to deteriorate during storage and diminish the usefulness of the drug. Additionally, the prior art devices lacked a port for filling the chamber, and if they were filled by puncturing with a hollow needle, the device failed to function either because of osmotic pressure leakage at the puncture site or the device hecame contaminated resulting from mixing of solute and agent arising at the site the inner wall was pierced. Thus, it will be appreciated by those skilled in the art that while the prior art devices made a valuable contribution to the art, the above mentioned disadvantages tended to restrict their use to a few environments.

OBJECTS OF THE INVENTION Accordingly, it is an immediate object of this invention to provide a novel dispensing device for the dispensing of agent to produce a beneficial effect, which device overcomes the aforesaid disadvantages associated with the prior art devices. v

Still another object of the invention is to provide a novel osmotic dispensing device for dispensing an agent at a controlled rate for a prolonged period of time.

Yet still another object of this invention is to provide a novel and useful osmotic dispensing device that is simple in construction, designed with a minimum number of parts, easy to use, and in operation is practical and useful for the controlled, continuous, long-term administration of an agent.

Still another object of the invention is to provide an osmotic dispensing device that has a separate port for filling the device which is self closing to maintain the integrity of the device.

Yet still another object of the invention is to provide an osmotic dispensing device that can be filled with agent when needed from a separate source through a self closing port integral in the device.

Still a further object of the invention is to provide an osmotic dispensing device that is empty until charged and then can administer a complete pharmaceutical dosage regimen for a period of time, the use of which requires intervention only for initiation and termination of the regimen.

Yet another immediate object of this invention is to provide a dispensing device that can be filled with drug at the time of use for administering a drug to produce a locally acting or systemically acting drug to produce a physiologic or pharmacologic effect which device can release the drug at a rate that does not vary with time.

Other objects, features, and advantages of the invention will be apparent to those skilled in the art, from the detailed description of this specification, taken in conjunction with the drawings and the accompanying claims.

SUMMARY OF THE INVENTION The invention concerns a device comprised of an outer wall surrounding an inner wall that defines a compartment as a means for containing an agent. A layer of an osmotically effective solute capable of exhibiting an osmotic pressure gradient against an external fluid is housed between th outer and inner'wall. A dispensing passageway leads from the compartment to the exterior of the device for releasing agent from the device. A filling passageway leads from the exterior of the device to the compartment and'it houses a means for closing the passageway. The outer wall of the device isformed of a material having shape retaining properties and it is permeable to an external fluid and substantially impermeable to solute. The inner wall is formed of a material essentially impermeable to external fluid and solute and collapsable when force is exerted thereon. In operation, external fluid permeates at a rate controlled by the wall permeability, wall dimensions, and osmotic pressure gradient into the solute causing it to increase in volume. The increased volume generatesa mechanical or hydrostatic compressing or deflating pressure on the collapsable wall, which pressure, negligible to the equilibrium in osmotic pressure of the fluid, in turn ejects the active agent out of the chamber at an osmotic-permeation controlled rate over a prolonged and continuous period of time.

BRIEF DESCRIPTION OF THE DRAWINGS In the drawings, which are not drawn to scale, but rather are set forth to illustrate various embodiments of the invention, the drawings are as follows:

FIG. 1 is an elevated illustration of an osmotic dispenser of the invention.

FIG. 2 is a cross-sectional view of FIG. 1 through 2-2 illustrating the structure of the device of FIG. 1.

FIG. 3 is a perspective, top view of a dispensing device of the invention illustrating another embodiment of the invention.

FIGS. 4 through 7 represent a graphic illustration of osmotic pumps showing their release rate from the devices over a prolonged period of time.

In the drawings and specification, like parts in related figures are identified by like numbers. The terms appearing earlier in the specification and in the description of the drawings, as well as embodiments thereof, are further described elsewhere in the disclosure.

DETAILED DESCRIPTION OF THE DRAWINGS Turning now to the drawings in detail, which are examples of various delivery devices of the invention, and which examples are not to be construed as limiting, one embodiment of a novel osmotic delivery device is indicated in FIG. 1 by the number 10. Delivery device 10 is comprised of a body portion 11, a discharge passageway 12 and a filling passageway 13 integrally formed with device 10. A means 14 for self closing filling passageway 13 is seen in broken lines in passageway 13.

Device 10 of FIG. 1 is seen in FIG. 2 in open section through 2-2 of FIG. 1. In FIG. 2, device 10 is comprised of a body 11 formed of an inner wall 15 formed of a flexible material collapsable in response to pressure and relatively impervious to fluid as osmotic solute, the wall surrounds and forms a compartment 16 defined by wall 15s inner surface. Compartment 16 is a means for containing an active agent and it is pro- Vided with a means 17 for dispensing the agent to the 1 exterior of device 10. Compartment 16 is further provided with a means 18 for filling compartment 16. Means 18, also referred to as filling port or filling passageway is Provided with a means 14 for self closing passageway 18. Closing means 14 is made from a material that is essentially impermeable and inert to agent form properties across all its dimensions, that is, it is substantially imperforate or substantially homogenous, or wall 20 can be formed of a material that is microporous.

In FIG. 2, positioned between wall 20 and wall 15 is I a layer 21 of an osmotically effective solute that exhibits an osmotic pressure gradient against an external fluid, when the device is positioned in the environment of use. In operation, these solutes osmotically attract fluid through the semi-permeable membrane 20 to pro duce a solution of the solute which increases in volume while simultaneously generating mechanical or hydrostatic force that is exerted against wall 15 to cause it to correspondingly collapse. As wall 15 collapses it ejects active agent out of chamber 16 through dispensing passageway 17 to the exterior of device. 10 at an osmotically membrane controlled rate over a prolonged period of time.

FIG. 3 illustrates another embodiment of the invention. In FIG. 3, device 10 is illustrated comprised of a body 11 having a pair of ports 22 each distant from the other. Ports 22 can be optionally used as filling ports or discharge ports and each houses a material 14 for closing the port after penetrated by a needle. Additionally,

either port can be equipped with a needle for discharging agent from device 10.

DETAILED DESCRIPTION OF THE INVENTION In accordance with the practice of the present invention, it has now been found that the osmotic delivery device of the invention provides many important advantages over previously known osmotically operated delivery devices. One advantage of the device is the ease of construction of the drug delivery device by standard manufacturing techniques into devices of various shapes and forms for delivering agent to recipient or environment. A more important advantage of the claimed delivery device is that it can be manufactured comprised of a minimum number of parts.

Another important advantage for osmotic delivery device 10 is the device and its agent can be separately stored and the device charged with agent at the time of use. This feature prevents or substantially reduces deterioration of the agent since agents susceptible to deterioration can be stored in glass containers and charged into the device at the time of use. Yet another important advantage for the devices of this invention resides in the users option to formulate special agents or compositions of agents that can be charged into the compartment at the time of use and at the environment of use. Another important advantage for the device resides in the device entering the commerical stream uncharged with agent in a simple sterile package. The feature enhances the utility of the device and simultaneously makes it possible to design special devices for special application that can be charged with agent at the environment of use. These features and other advantages are made available to the art by the invention providing the device with a filling port generally positioned distant from the discharge port. The filling port is equipped with a self sealing or self closing stopper or bung that fills the internal space of the filling port and can be repeatedly penetrated and closed following withdrawal by a penetrating instrument. The filling port housing the bung is constructed with the wall in intimate contact with the bung by shrinking the wall to the bung during fabrication of the device. This unique feature of the device also makes it possible to fill the device with agent without developing air pockets in the compartment and without penetrating the devices walls which could lead to a loss of osmotic pressure and leakage. Additionally, another advantage for the novel osmotic pump is that pumps made with along and narrow catheter which could not be filled heretofore can now be filled by entering the chamber through filling port equipped with the bung.

Wall 20 of the device is a material that is semipermeable, for example a material that is permeable to an external fluid such as water and the like while essentially impermeable to a selected product or to other compounds in the device. The material forming the wall can be non-erodible or bioerodible after a predetermined period of time and in each instance it is semipermeable to external fluid but not to solute and is suitable through its shape retaining properties during its useful life for construction of the osmotic powered device. Typical materials for forming the wall include membranes known to the art as osmosis and reverse osmosis membranes such as commercially available unplasticized cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose nitrate with 1 1 percent nitrogen, cellulose diacetate, cellulose triacetate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, celluloseacetate, acetaldehyde dimethyl acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulfonate, cellulose acetate butyl sulfonate, cellulose acetate propionate, cellulose acetate p-toluene sulfonate, triacetate of locust gum bean, cellulose acetate with acetylated hydroxyethyl cellulose, hydroxylated ethylene-vinylacetate, cellulose acetate butyrate having a viscosity of from about seconds to about 50 seconds, cellulose acetate butyrate containing about 17 percent of combined butyryl and about 29.5 percent acetyl permselective, aromatic nitrogen-containing polymeric membranes that exhibit water permeability and essentially no solute passage, osmosis membranes made from polymeric epoxides, osmosis membranes made from copolymers of an alkylene oxide and alkyl glycidyl ether, semi-permeable polyurethanes, semi-permeable polyglycolic or polylactic acid and derivatives thereof, thin film membranes as disclosed by Loeb and Sourirajan in U. S. Pat. No. 3,133,132, the membranes of ionically associated polyelectrolytes, the polymers formed by the coprecipitation of polycation and a polyanion as described in U. S. Pat. Nos. 3,276,586; 3,541,005; 3,541,006; 3,546,142; 3,173,876; derivatives of polystyrene such as poly(sodium styrenesulfonate) and poly(vinylbenzyltrimethylammonium chloride), and the like. Generally, membranes having a fluid permeability of 0.01 to 10 cclcm /hour or day or higher at atmosphere pressure against a saturated product solution or saturated solute solution to a changing concentration at the temperature of use while simultaneously possessing a high degree of impermeability to the product or solute are useful and within the spirit of the invention.

Wall 15, or the inner wall of the device that defines the compartment and is in intimate contact with bung 14 is a heat shrinkable, polymeric material that collapses on the application of force thereto and simultaneously maintains the self sealing bung in the filling port. The polymeric membrane is selected from the class of heat shrinkable polymeric films in the form of tubes, spheres, ellipsoids, envelopes, films, laminates, and other geometric shapes and fabricated structures is in one embodiment a material that has been prepared by inducing strong molecular orientation by uni-axially or bi-axially stretching of the film, which operation, preferably, can be preceded by the introduction of inter-molecular primary valence cross-linkage by chemical or radiation processes. The degree of cross-linking, when employed, should be sufficient to impart to the film a thermoset character, which can be'conveniently defined as the ability to exhibit a minimum tensile strength of about 50 lbs./in. at a temperature of 300F. By heat shrinkable" is meant in'this embodiment that the film can contract by at least 10 percent and typically from about 25 percent .tO 75 percent of its stretched dimension in one or more directions upon heating. The material is expanded or stretched mechanically, hydraulically, or pneumatically, either uniaxially or bi-axially, at room temperature or elevated temperatures, and then is set or fixed, or frozen, into this expanded, high energy state. Procedures for accomplishing this are well known in the polymer fabrication art. For example, in the manufacture of bi-axially oriented, heat" shrinkable flim, the film is prepared by extrusion through a shaping die with a long, narrow horizontal slit of such width as to give the desired film thickness. As the hot ribbon of polymeric material issues from the die, it is gripped along its two edges by tenter hooks which tend to stretch the film along its width and to stretch it in a forward direction at the same time. This operation imparts bi-axial orientation and yields a film with equal shrinkage along both axes. Typically, such a film will have a potential shrinkage of 50 percent in both directions. Not only is the rate of stretching important in achieving this result, but the rate of cooling and the temperature profile during the stretching are important. As described here, this operation is done in-line with extrusion, but it can also be done on preformed film by heating and stretching the film.

In the manufacture of one type of heat shrinkable tubing for use in the present invention, the polymer is first prepared in tubular shape, preferably by extrusion through a die of the desired cross-sectional configuration. The tubing can then be subjected to ionizing radiation consisting of a stream of high energy electrons as delivered by a van de Graaff generator or other electron accelerating equipment. Or the tubing can be treated with gamma rays as emanating from cobalt-60. The dosage delivered can vary, depending upon the polymer system, from 0.5 to megarads to achieve the desired degree of intermolecular cross-linkage. The tubing is then subjected to uni-axial molecular orientation by drawing it, optimally in a warm or heated condition, over an appropriately shaped mandrel, which increases the cross-sectional area by a factor of 2 to 16. The polymer, having been selected from classes which tned to have high intermolecular attraction, will tend to remain in the high energy, stretched stateuntil heated above a temperature at which these intermolecular attractions are melted or released. The memory or tendency to recover back to the unstretched state is encouraged by the cross-linkage which was introduced by the earlier radiation treatment.

- Polymeric membranes preferably are cross-linked prior to stretching and using to form the inner wall. The chemical cross-linking of these polymers can be achieved by incorporation of various cross-linking agents such as peroxides, sulfur, metallic oxides, selenium, tellerium, diamines, diisocyanates, alkyl phenol disulfides, p-quinone dioxime, tetra-chloro-pbenzoquinone, tetra alkyl thiuram disulfides, 4,4- dithiomorpholine, sulfur dichloride, and the like, into the polymer followed by a period of heating. Alternatively, cross-linking or vulcanization can be achieved by use of high energy electron-beam radiation such as is provided by a van de Graaff generator or other types of electron accelerators, or by gamma ray emitters, or

by X-ray generators.

In another embodiment pre-oriented shrinkable materials suitable for forming the chamber and housing the self sealing bung by engaging the bung when the film is exposed to heat comprise oriented film of vinyl chloride polymer which has a Youngs modulus of elasticity in both directions of at least 200,000 p.s.i. l4,000 kglcm at 23C, a shrinkage of at most 35 per cent at p.s.i. (l0.5 kglcm at any temperature. The films preferably have shrink tensions not exceeding 100 p.s.i. (7 kglcm at any temperature. The most preferred film is a rigid (i.e. unplasticized) polyvinyl chloride filmwhich is 0.01 to 0.95 mm thick and has been bi-axially oriented so that it has a shrinkage in both directions of at most about 20 percent, especially 15 to 20 percent, e.g. about 20 percent. Films having low degrees of orientation or shrink in one direction only, such as are produced directly by some extrusion methods, can be used in accordance with the invention, but require the use of rather high film temperatures, near the melting point of the polymer, in order sufficiently to shrink the film. Accordingly it is preferred to use films which have been bi-axially oriented so that they have percent shrinkages at 100C in both directions of to 35 percent, especially to 25 percent, particularly 15 to percent, and have shrink tensions not exceeding 150 p.s.i. (10.5 kglcm and preferably not exceeding 100 psi. (7.0 kglcm at any temperature; such films are believed to be novel. They can be very satisfactorily used in shrink packaging procedures in which the film only has to reach a maximum temperature of 120C and for regular objects 100C or even less.

The vinyl chloride polymer shrinkable materials used herein include homopolymers and copolymers such as vinyl chloride and vinyl acetate, styrene, acrylonitrite, dialkyl fu'marate or maleate, or alkyl acrylate or methacrylate, vinyl acetate and vinylidene chloride, blends of polyvinyl chloride with chlorinated polyethylene or terpolymer, and the like. Other heat shrinkable materials include vinylidene chloride, copolymers of vinylidene chloride of 20 to 80 percent vinylidene chloride, copolymers of vinylidene chloride and vinyl chloride and the like. Heat shrinkable materials are set forth in US. Pat. Nos. 3,022,543; 3,419,421; 3,459,582; 3,614,852; 3,627,116; and the like.

Various osmotically effective solutes including organic and inorganic compounds are advantageously used for coating on the exterior surface of the inner wall to act as a means for generating osmotic pressure. Suitable solutes exhibit an osmotic pressure gradient against an external fluid across the semi-permeable membrane which membrane is substantially impermeable to the passage of the osmotically effective solute to prevent loss thereof through the membrane. Various osmotically effective solutes include compounds such as magnesium sulfate, magnesium chloride, sodium chloride, lithium chloride, potassium sulfate, sodium carbonate, sodium sulfite, lithium sulfate, calcium bicarbonate, sodium sulfate, calcium sulfate, potassium acid phosphate, calcium lactate, magnesium succinate, tartaric acid, soluble carbohydrates such as raffinose, glucose, mixtures thereof and the like.

Additionally, the solute can be used in a mixed form by mixing the compound with a binder. The'solute in powdered, granular, piece and the like form, is homogenously or heterogenously dispersed in the binder which binder is soluble or insoluble but will release the solute on contact with wall material. Typical binders include polyethylene glycol, gelatin, agar, carboxycellulose, ethylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, soluble starch derivatives and the like. Typical binders that can comprise about 1 to 50 percent of the composition include cellulose acetate, polyurethane, epoxides, and other binders that permit the free movement of fluid into the solute of the layered structure to permit the solute to increase in volume and generate osmotic pressure.

The stopper or bung, as confined in the filling passageway, is comprised of naturally occurring or synthetic material that possesses self closing or self sealing properties following the withdrawal therefrom of a piercing instrument. These materials are generally known to the art as elastomers, and they include the commercially available carboxylated butadiene acrylonitrile copolymers, butadiene vinylpyridine copolymers, polychloroprene, isoprene, copolymerized with piperylene, polyisoprene, poly(butadiene-co-styrene), poly(butadiene-co-acrylonitrile), natural rubber, poly- (isobutylene-co-isoprene), silicones, fluroelastomers, butyl rubber, halogenated butyl rubber, poly(butadiene-styrene-vinylpyridine) acrylic rubbers, butadiene:acrylonitrite /20, 73/27, 68/32, 61/39, free radical cross-linked silicone elastomers, and the like.

The phrase active agent and the term agents" as used throughout the specification and the accompanying claims comprises any compound, or mixture of compounds, composition of matter or mixture thereof that can be dispensed from the device to produce a predetermined beneficial and useful result. The active agents include pesticides, germicides, biocides, algicides, rodenticides, fungicides, insecticides, antioxidants, plant growth promoters, plant growth inhibitors, preservating agents, surfactants, disinfectants, sterilization agents, catalysts, chemical reactants, fermentation agents, cosmetics, foods, nutrients, food supplements, drugs, vitamins, sex sterilants, fertility inhibitors, fertility promotors, air purifiers, microorganism attenuators, and other like agents that benefit the environment, surroundings, and habitat including animals, mammals, man, valuable farm animals, household animals, sport animals, and the like.

ln a presently preferred embodiment the active agent is a drug that will produce a local or systemic physiologic or pharmacologic response when administered to animals, including humans, avians, and the like. Suitable drugs that are dispensed in conventional, standard dosage amounts as known to the art comprise desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen; vaccines such as small pox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, diphtheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influen' zae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc; anti-infectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline, bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other anti-infectivesincluding nitrofurazone and sodium propionate; anti-allergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine; anti-inflammatories such as hydrocortisone, cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2 1 phosphate,fluocinolone, triamcinolone, medrysone,

prednisolone, prednisolone 2 1 -phosphate, and prednisolone acetate; decongestants such as phenylephrine, naphazoline, and tetrahydrozoline; miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, di-isopropyl fluorophosphate, phospholine iodide, and demecarium bromide; mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine; sympathomimetics such as epinephrine; sedatimes and hypnotics such as pentobarbital sodium, phenobarbital, secobarbital sodium, codeine, (a-bromo-isovaleryl) urea, carbromal; psychic energizers such as 3-( 2-aminopropyl) indole acetate and 3-( 2- aminobutyl) indole acetate; tranquilizers such as reserpine, chlorpromazine, and thiopropazate; androgenic steroids such as methyltestosterone and fluoxymesterone; estrogens such as estrone, 17 B-estradiol, ethinyl estradiol, and diethyl stilbesterol; progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, l9-norprogesterone, norethindrone, medroxyprogesterone and 17 a-hydroxyprogesterone; humoral agents such as the prostaglandins, for example POE PGE and PFD antipyretics such as aspirin, sodium salicylate, and salicylamide; anti-spasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide; anti-malarials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine; antihistamines such as diphenhydramine, dimehydrinate, tripelennamine, perphenazine, and carphenazine; cardioactive agents such as hydrochlorothiazide, flumethiazide, chlorothiazide, and trolnitrate; nutritional agents such as vitamins, essential amino acids and essential fats; anti-Parkinsonism agents such as L-dopa, (L-3,4-dihydroxyphenylalanine); investigative antihypotensive agents such as dopamine, 4-(2- aminoethyl) pyrocatechol. Other agents having the same or different physiological activity as those recited above can be employed in osmotic dispensers within the scope of the present invention. Suitable mixtures of drugs can, of course, be explained with equal facility as with single component systems.

The agent can be in various forms, such as unchanged molecules, components of molecular complexes, or non-irritating pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, and the like. For acidic drugs, salts of metals, amines, or organic cations, for example, quaternary ammonium can be employed. Furthermore, simple derivatives of the drugs such as ethers, esters, amides, and the like which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes and the like can be employed. The amount of agent incorporated in the osmotic dispenser varies widely depending on the particular agent, the desired therapeutic effect, and the time span for which it takes the agent to be released. Since a variety of dispensers in a variety of sizes and shapes are intended to provide complete dosage regimens for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the dispenser. The lower limit too will depend on the activity of the drug and the time span of its release from the dispenser. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the dispenser. Thus, the amount dispensed for active agents such as drug will be the standard amount as described in Pharmacology in Medicine, edited by DiPalma, J.R.., 1965, McGraw-l-lill Book Company, New York; The Pharmacological Basis of Therapeutics, Fourth Edition, by Goodman, LS. and Gilman, A.,

Pharmaceutical Sciences, Fourteenth Edition, i970, Mack Publishing Company, Easton, Penn; and the like. Additionally, the drug can be charged into the device in known forms such as solution, dispersion, cream, emulsion, suspensions, fine powders, and the like. Generally, the device will contain about 0.01 to percent or higher of an agent or a mixture of agent and carriers based on the weight of the agent or agent carriers composition solute to the volume of the device, and the like. Typically, the device can be of such size and shape to release 0.01 cc to 5 cc or higher of agent, usually contained in a pharmaceutical carrier, per hour, day or longer, such as 1 cc to 10 cc of agent composition for l to 10 days, and the like.

The expressions passageway and passageway communicating with" as used herein are comprised of those means and methods suitable for releasing the product from the device under the pumping rate of the device. The expression includes an aperture, orifice, bore, stainless steel needles, hollow cellulose acetate tubes, polyolefin tubes, capillary tubes suitable for passing the agent, tubes and conduits of various inside diameters, closed passageways containing a bioerodible material that erodes in the environment of use to produce an open passageway. Typical bioerodible materials include erodible polyglycolic and polylactic fibers, erodible gelatinous filaments, polyvinyl alcohol, and the like.

The following examples are merely illustrative of the present invention and they should not be considered as limiting the scope of the invention in any way, as these examples and other equivalents thereof will become apparent to those versed in the art in the light of the present disclosure, drawings, and the accompanying claims.

An osmotic dispensing device for the continuous release of active agent and having a diameter volume of microliters was manufactured as follows: first, a section of commerically available heat shrinkable poly- (olefine) such as poly(vinylidene chloride) having an internal diameter three thirty-seconds inches was cut into a 5 cm section. Next, a plug of commerically available Silastic silicone rubber was cut from a rod, with the plug having the following dimensions 3 mm long X 3 mm O.D. wherein 0D. is outside diameter. Then, the plug was inserted into the heat shrinkable tubing and held in position between two solid steel rods. One rod entered the tubing from each of its entrances. The unit was heated at 100C in water and pulled longitudinally until the gap between the plug and the rod was 2 mm longer than a mold cavity used for the pulling step. The mold cavity was 7 mm long,

The tubing containing the plug was cooled to room temperature and clamped into ajsecond mold with a milled cavity and a clamping means for confining the encapsulated silicone rubber.- The mold was closed and heated at 100C in water with pressure applied for 30 seconds through one opening of the tubing to expand the tubing to the dimensions of the cavity. The mold was next cooled and tubing housing the plug and having a cavity was removed from the mold.

Next, an osmotic solute slurry was prepared by mixing 500 grams of analytical reagent grade K 80 powder with 200 ml of 2 wt percent ethyl cellulose in ethanol in a Waring blender at the highest speed for about 2 minutes. The appropriate amount of solute was deposited on 15 chambers by dips in the cooled solute slurry with minute intervals between dips. The slurry coated chambers were placed in a near zero humidity dry box to prevent water absorption during evaporation of solvent. A few of the chambers were optionally dipped in gelatin to smooth any pores and add strength to the solute deposit. When gelatin was applied, the gelatine dip was 15 g in 100 ml of distilled water at 60C. All the coated chambers were dried at least 2 hours. The total solute coat thickness was measured at about 0.27 mm.

Next, the dry solute coated chambers were placed in a dipping box containing an acetone atmosphere for dipping in a freshly prepared cellulose acetate membrane solution comprised of IS wt percent cellulose acetate and 85 wt percent acetone. The chambers were dippsed 14 times with 15 minute intervals between dips to deposit a membrane about 14 mils thick.

Four osmotic dispensing devices manufactured according to the above description were changed with a blue dye solution and the dye release rate measured and charted in accompanying FIGS. 4, 5, 6 and 7. The osmotic pumps were placed in an environment of water which was an external fluid. The dispensed blue dye is measured volumetrically or by using standard otpical laboratory measuring instruments. The results obtained show that after a short start-up period, the osmotic devices uniformly dispense about 0.6 p.l/hr. The prolonged and constant pumping rate is obtained to exhaustion of the chamber, or for about 150 hours, and the total volume dispensed from the devices was about 92 ,LLl. The results for the devices measured as shown in FIGS. 4 7 are seen as evidencing the useful operability of the device for its application in industry and commence.

The novel, osmotic product delivery device of this invention employs a unique means which facilitates the obtainment of precisely conducted agent release rates in the environment of use. While there has been described and pointed out the fundamental novel features of the invention as applied to the presently preferred embodiments, those skilled in the art will appreciate that various modifications changes and omisslons in the osmotic agent devices illustrated and described can be made without departing from the spirit of the invention.

What is claimed is:

1. An osmotic dispenser for dispensing an active agent, wherein said dispenser comprises:

a. an inner wall formed of a fexible material essentially impermeable to solute and external fluid, the

wall surrounding and forming,

b. a compartment defined by the inner surface of the wall as a means for housing an active agent,

c. a layer of an osmotically efi'ective solute deposited on the inner walls outer surface, said solute capable of exhibiting an oxmotic pressure gradient against an external fluid when the dispenser is positioned in the environment of use,

d. an outer wall surrounding the layer of solute, said outer wall formed of a material having shape retaining properties and at least a part of the wall is permeable to external fluid and impermeable to solute,

e. a dispensing passageway communicating with the compartment and the exterior of the device for dispensing an agent from the device,

f. a filling passageway communicating with the exterior of the device and the compartment as a means for charging agent into the compartment,

g. a means positioned in the filling passageway for closing the passageway, said means formed of a material that automatically closes after agent is charged into the compartment through the filling passageway.

2. An improved osmoticdispenser for dispensing an active agent according to claim 1 wherein the inner wall material is a heat shrinkable polymeric material.

3. An improved osmotic dispenser for dispensing an active agent according to claim 1 wherein the automatic closing material is an elastomeric material.

4. An improved osmotic dispenser for dispensing an active agent'according to claim 1 wherein the filling passageway is formed of a heat shrinkable polymer in intimate contact with the automatic closing material formed of an elastomeric material.

5. An improved osmotic dispenser for dispensing an active agent according to claim 1 wherein in operation in the environment of use, agent is dispensed from the dispensor by external fluid permeating from the exterior through the permeable outer wall continuously dissolving the solute in a tendency toward osmotic equilibrium with the environment to continually increase the volume between the outer wall and the compartment generating a mechanical or hydrostatic force to cause the compartment to continuously collapse and dispense agent from the device at a controlled rate over a prolonged period of time through the dispensing passageway with essentially no agent dispensed through the filling passageway.

IF k

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3604417 *31 Mar 197014 Sep 1971American Cyanamid CoOsmotic fluid reservoir for osmotically activated long-term continuous injector device
Non-Patent Citations
Reference
1 *Australian Journal Experimental Biology (1955), 33, pp. 415 420.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3865108 *9 Jul 197311 Feb 1975Ortho Pharma CorpExpandable drug delivery device
US3880164 *22 May 197229 Apr 1975Alza CorpOsmotic wound drain
US3894538 *6 Aug 197315 Jul 1975Siemens AgDevice for supplying medicines
US3952741 *9 Jan 197527 Apr 1976Bend Research Inc.Controlled release delivery system by an osmotic bursting mechanism
US3987790 *1 Oct 197526 Oct 1976Alza CorporationOsmotically driven fluid dispenser
US3995631 *25 Sep 19727 Dec 1976Alza CorporationOsmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4031202 *8 Dec 197521 Jun 1977The Procter & Gamble CompanyControlled release contraceptive article
US4034756 *12 Mar 197612 Jul 1977Alza CorporationOsmotically driven fluid dispenser
US4054138 *12 May 197618 Oct 1977Louis BucaloImplants for acting on living beings
US4073833 *8 Dec 197514 Feb 1978The Procter & Gamble CompanyEncapsulation process
US4111201 *22 Nov 19765 Sep 1978Alza CorporationOsmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202 *22 Nov 19765 Sep 1978Alza CorporationOsmotic system for the controlled and delivery of agent over time
US4111203 *22 Nov 19765 Sep 1978Alza CorporationOsmotic system with means for improving delivery kinetics of system
US4177256 *29 Nov 19774 Dec 1979Alza CorporationOsmotic bursting drug delivery device
US4180073 *29 Aug 197725 Dec 1979Alza CorporationDevice for delivering drug to biological environment
US4203440 *23 Oct 197820 May 1980Alza CorporationDevice having variable volume chamber for dispensing useful agent
US4203442 *4 Jan 197920 May 1980Alza CorporationDevice for delivering drug to a fluid environment
US4207893 *26 Dec 197817 Jun 1980Alza CorporationDevice using hydrophilic polymer for delivering drug to biological environment
US4223061 *25 Oct 197716 Sep 1980Alza CorporationHydrophilic laminate useful for making dispensing device
US4237893 *28 Nov 19799 Dec 1980Alza CorporationCervical dilator
US4304232 *28 Jan 19808 Dec 1981Alza CorporationUnit system having multiplicity of means for dispensing useful agent
US4432756 *27 Nov 198121 Feb 1984Alza CorporationParenteral controlled therapy
US4473370 *14 Sep 198125 Sep 1984Weiss Jeffrey NProtective eye shield
US4479793 *11 Oct 198330 Oct 1984Alza CorporationParenteral administration using drug delivery device
US4479794 *11 Oct 198330 Oct 1984Alza CorporationSystem for intravenous therapy
US4484909 *17 Oct 198327 Nov 1984Alza CorporationParenteral therapy using solid drug
US4493702 *17 Oct 198315 Jan 1985Alza CorporationParenteral administration using osmotically motivated delivery system
US4511351 *14 May 198416 Apr 1985Alza CorporationParenteral delivery system utilizing a hollow fiber cellular unit
US4511352 *14 May 198416 Apr 1985Alza CorporationParenteral delivery system with in-line container
US4511353 *9 Oct 198116 Apr 1985Alza CorporationIntravenous system for delivering a beneficial agent
US4515585 *31 Oct 19837 May 1985Alza CorporationSystem for parenteral administration of agent
US4525162 *9 Mar 198425 Jun 1985Alza CorporationParenteral controlled delivery
US4548599 *5 Jan 198422 Oct 1985Alza CorporationParenteral controlled therapy
US4552556 *4 Jan 198512 Nov 1985Alza CorporationParenteral controlled therapy
US4579553 *7 Jan 19851 Apr 1986Alza CorporationParenteral controlled therapy
US4583981 *7 Jan 198522 Apr 1986Alza CorporationParenteral controlled therapy, using a porous matrix with parenteral agent
US4586922 *15 Feb 19856 May 1986Alza CorporationIntravenous system for delivering a beneficial agent
US4596555 *28 Jan 198524 Jun 1986Alza CorporationParenteral delivery system utilizing a hollow fiber cellular unit
US4663148 *14 Feb 19865 May 1987Alza CorporationDispenser comprising telescopically engaging members
US4663149 *14 Feb 19865 May 1987Alza CorporationDispenser comprising inner and outer walls functioning as cooperative unit
US4664650 *31 Oct 198312 May 1987Alza CorporationApparatus for parenteral infusion of fluid containing beneficial agent
US4692326 *14 Feb 19868 Sep 1987Alza CorporationDispenser comprising inner positioned soft or hard capsule
US4716031 *12 Feb 198629 Dec 1987Alza CorporationDrug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4740103 *15 Feb 198526 Apr 1988Alza CorporationIntravenous system for delivering a beneficial agent
US4740197 *14 Feb 198526 Apr 1988Alza CorporationIntravenous system for delivering a beneficial agent via polymer delivery
US4740198 *15 Feb 198526 Apr 1988Alza CorporationMethod of administering intravenous drug using rate-controlled dosage form
US4740199 *14 Feb 198526 Apr 1988Alza CorporationIntravenous system for delivering a beneficial agent
US4740200 *15 Feb 198526 Apr 1988Alza CorporationIntravenous system for delivering a beneficial agent
US4740201 *19 Feb 198526 Apr 1988Alza CorporationIntravenous system for delivering a beneficial agent
US4741734 *15 Feb 19853 May 1988Alza CorporationReleasing means for adding agent using releasing means to IV fluid
US4741735 *14 Feb 19853 May 1988Alza CorporationIntravenous system for delivering a beneficial agent
US4790820 *25 Oct 198413 Dec 1988Alza CorporationParenteral agent dispensing equipment with drug releasing member
US4800056 *14 Feb 198624 Jan 1989Alza CorporationProcess for making dispenser with cooperating elements
US4814180 *15 Dec 198621 Mar 1989Alza CorporationAgent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US4857052 *4 May 198715 Aug 1989Alza CorporationIntravenous system for delivering a beneficial agent
US4865845 *28 Aug 198712 Sep 1989Alza CorporationRelease rate adjustment of osmotic or diffusional delivery devices
US4871360 *21 Apr 19863 Oct 1989Alza CorporationSystem for intravenous delivery of a beneficial drug at a regulated rates
US4908019 *16 Sep 198813 Mar 1990Alza CorporationApparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4929233 *26 Aug 198829 May 1990Alza CorporationImplantable fluid imbibing pump with improved closure
US4946456 *26 Aug 19887 Aug 1990Alza Corp.Fluid imbibing pump activated by capillary action of a fabric or polymeric sleeve
US4969872 *8 Mar 198913 Nov 1990Alza CorporationIntravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
US4969884 *28 Dec 198813 Nov 1990Alza CorporationOsmotically driven syringe
US4973307 *25 Apr 198927 Nov 1990Alza CorporationMethod for administering drugs to a patient
US4976966 *29 Dec 198811 Dec 1990Alza CorporationDelayed release osmotically driven fluid dispenser
US4985017 *25 Apr 198915 Jan 1991Alza CorporationParenteral therapeutical system comprising drug cell
US4994031 *17 Apr 198919 Feb 1991Alza CorporationIntravenous system for delivering a beneficial agent
US5024657 *4 May 199018 Jun 1991Baxter International Inc.Drug delivery apparatus and method preventing local and systemic toxicity
US5024663 *21 Feb 199018 Jun 1991Alza CorporationSelf-contained suction pump
US5030203 *16 Nov 19879 Jul 1991Baxter International Inc.Ampule for controlled administration of beneficial agent
US5030216 *15 Dec 19899 Jul 1991Alza CorporationOsmotically driven syringe
US5069671 *23 Jun 19883 Dec 1991Alza CorporationIntravenous medication
US5151093 *29 Oct 199029 Sep 1992Alza CorporationOsmotically driven syringe with programmable agent delivery
US5279608 *4 Dec 199118 Jan 1994Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)Osmotic pumps
US5312389 *3 Apr 199217 May 1994Felix TheeuwesOsmotically driven syringe with programmable agent delivery
US5540665 *31 Jan 199430 Jul 1996Alza CorporationGas driven dispensing device and gas generating engine therefor
US5972369 *30 Mar 199826 Oct 1999Alza CorporationDiffusional implantable delivery system
US6180129 *23 Oct 199730 Jan 2001Alza CorporationPolyurethane-containing delivery systems
US62514321 Jul 199926 Jun 2001Abbott LaboratoriesSustained release dosage form unit having latex coating and method of making the same
US634793410 May 200019 Feb 2002E. Khashoggi Industries, Llc.System for metering and delivering a moldable composition into a mold
US646468815 Feb 200015 Oct 2002Microsolutions, Inc.Osmotic pump delivery system with flexible drug compartment
US647168815 Feb 200029 Oct 2002Microsolutions, Inc.Osmotic pump drug delivery systems and methods
US654102110 Mar 20001 Apr 2003Durect CorporationDevices and methods for pain management
US661665215 Feb 20009 Sep 2003Microsolutions, Inc.Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
US662043410 May 200116 Sep 2003Abbott LaboratoriesSustained release dosage form unit having latex coating and method of making the same
US6627631 *8 Feb 200030 Sep 2003Lts Lohmann Therapie-Systeme AgPharmaceutical composition containing desoxypeganine for the treatment of alcoholism
US663221719 Apr 200114 Oct 2003Microsolutions, Inc.Implantable osmotic pump
US668937326 Nov 200210 Feb 2004Durect CorporationDevices and methods for pain management
US677557018 Apr 200210 Aug 2004Ceramatec, Inc.Iontophoretic treatment device
US683519427 Jun 200228 Dec 2004Durect CorporationImplantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US69770742 Feb 200120 Dec 2005Mannkind CorporationMethod of inducing a CTL response
US699485110 Jul 19987 Feb 2006Mannkind CorporationMethod of inducing a CTL response
US70470694 Feb 200216 May 2006Ceramatec, Inc.Iontophoretic fluid delivery device
US7117870 *26 Jul 200410 Oct 2006Clarity CorporationLacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US725444927 Jan 20067 Aug 2007Advanced Bionics CorpSystems and methods for providing power to one or more implantable devices
US73351936 Jul 200426 Feb 2008Durect CorporationOsmotically-driven fluid dispenser
US734774627 Oct 200625 Mar 2008Boston Scientific Neuromodulation CorporationReceptacle connector assembly
US73497332 Nov 200125 Mar 2008Ceramatel, Inc.Iontophoretic drug delivery systems
US736472919 Dec 200529 Apr 2008Mannkind CorporationMethod of inducing a CTL response
US740797321 Oct 20045 Aug 2008Intermune, Inc.Use of pirfenidone in therapeutic regimens
US744552829 Sep 20064 Nov 2008Boston Scientific Neuromodulation CorporationConnector assemblies
US74837466 Dec 200527 Jan 2009Boston Scientific Neuromodulation Corp.Stimulation of the stomach in response to sensed parameters to treat obesity
US74931724 Mar 200517 Feb 2009Boston Scientific Neuromodulation Corp.Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
US761010030 Dec 200527 Oct 2009Boston Scientific Neuromodulation CorporationMethods and systems for treating osteoarthritis
US768485821 Sep 200523 Mar 2010Boston Scientific Neuromodulation CorporationMethods and systems for placing an implanted stimulator for stimulating tissue
US772975830 Nov 20051 Jun 2010Boston Scientific Neuromodulation CorporationMagnetically coupled microstimulators
US776946117 Dec 20043 Aug 2010Boston Scientific Neuromodulation CorporationSkull-mounted electrical stimulation system and method for treating patients
US777764129 Mar 200617 Aug 2010Advanced Bionics, LlcSystems and methods of facilitating communication between a first and second device
US779903711 Feb 200321 Sep 2010Boston Scientific Neuromodulation CorporationSurgical insertion tool
US783580317 Jan 200716 Nov 2010Boston Scientific Neuromodulation CorporationLead assemblies with one or more switching networks
US7846332 *25 Jun 20077 Dec 2010Mainstream Engineering CorporationApparatus and method for self-heating and self-hydrating foods and beverages
US784880326 Mar 20077 Dec 2010Boston Scientific Neuromodulation CorporationMethods and systems for facilitating stimulation of one or more stimulation sites
US785332125 Oct 200514 Dec 2010Boston Scientific Neuromodulation CorporationStimulation of a stimulation site within the neck or head
US789017617 Jun 200515 Feb 2011Boston Scientific Neuromodulation CorporationMethods and systems for treating chronic pelvic pain
US792091516 Nov 20055 Apr 2011Boston Scientific Neuromodulation CorporationImplantable stimulator
US7963935 *20 Apr 200221 Jun 2011Alza CorporationMicroprojection array having a beneficial agent containing coating
US809521923 Jan 200910 Jan 2012Boston Scientific Neuromodulation CorporationStimulation of the stomach in response to sensed parameters to treat obesity
US817571014 Mar 20068 May 2012Boston Scientific Neuromodulation CorporationStimulator system with electrode array and the method of making the same
US81978448 Jun 200712 Jun 2012Activatek, Inc.Active electrode for transdermal medicament administration
US821405812 Oct 20103 Jul 2012Boston Scientific Neuromodulation CorporationLead assemblies with one or more switching networks
US822445117 Nov 201017 Jul 2012Boston Scientific Neuromodulation CorporationMethods and systems for facilitating stimulation of one or more stimulation sites
US83157045 Nov 201020 Nov 2012Boston Scientific Neuromodulation CorporationStimulation of a stimulation site within the neck or head
US836428021 Jul 200929 Jan 2013Boston Scientific Neuromodulation CorporationEngagement tool for implantable medical devices
US83723933 May 200612 Feb 2013Mannkind CorporationMethod of inducing a CTL response
US840163431 Aug 201019 Mar 2013Boston Scientific Neuromodulation CorporationTreatment of movement disorders by brain stimulation
US840165430 Jun 200619 Mar 2013Boston Scientific Neuromodulation CorporationMethods and systems for treating one or more effects of deafferentation
US840465313 Nov 200626 Mar 2013Enterprise Partners Venture CapitalMembrane bound stem cell factor therapy for ischemic heart
US842315412 Jun 201216 Apr 2013Boston Scientific Neuromodulation CorporationLead assemblies with one or more switching networks
US84231558 Aug 200816 Apr 2013Boston Scientific Neuromodulation CorporationMethods and systems for facilitating stimulation of one or more stimulation sites
US845240729 Jul 200528 May 2013Boston Scientific Neuromodulation CorporationMethods for treating gastrointestinal disorders
US850416330 Jun 20066 Aug 2013Boston Scientific Neuromodulation CorporationCranially mounted stimulation systems and methods
US851554122 Dec 200520 Aug 2013Boston Scientific Neuromodulation CorporationMethods and systems for treating post-stroke disorders
US863070521 Mar 201114 Jan 2014Boston Scientific Neuromodulation CorporationImplantable stimulator
US864495415 Apr 20134 Feb 2014Boston Scientific Neuromodulation CorporationMethods and systems for facilitating stimulation of one or more stimulation sites
US886222318 Jan 200814 Oct 2014Activatek, Inc.Active transdermal medicament patch and circuit board for same
US909571330 Jun 20064 Aug 2015Allison M. FosterMethods and systems for treating autism by decreasing neural activity within the brain
US913856926 Feb 201322 Sep 2015SinuSys CorporationDevices and methods for dilating a paranasal sinus opening and for treating sinusitis
US914961620 May 20136 Oct 2015SinuSys CorporationDevices and methods for dilating a paranasal sinus opening and for treating sinusitis
US932706929 Mar 20063 May 2016Boston Scientific Neuromodulation CorporationMethods and systems for treating a medical condition by promoting neural remodeling within the brain
US93521452 Jul 200931 May 2016Boston Scientific Neuromodulation CorporationMethods and systems for treating a psychotic disorder
US93583939 Nov 20057 Jun 2016Andres M. LozanoStimulation methods and systems for treating an auditory dysfunction
US93644846 Dec 201214 Jun 2016The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions for treating viral diseases
US9416783 *22 Sep 201016 Aug 2016Ecp Entwicklungsgellschaft MbhCompressible rotor for a fluid pump
US949823926 Aug 201122 Nov 2016SinuSys CorporationDevices and methods for inserting a sinus dilator
US950481220 May 201329 Nov 2016SinuSys CorporationDevices and methods for dilating a paranasal sinus opening and for treating sinusitis
US959748520 May 201321 Mar 2017SinuSys CorporationDevices and methods for dilating a paranasal sinus opening and for treating sinusitis
US962964426 Aug 201125 Apr 2017SinuSys CorporationDevices and methods for dilating a paranasal sinus opening and for treating sinusitis
US968726329 May 201427 Jun 2017SinuSys CorporationDevices and methods for inserting a sinus dilator
US20010047161 *30 Jan 200129 Nov 2001Wong Patrick S.L.Osmotically-driven fluid dispenser and composition
US20020007173 *2 Feb 200117 Jan 2002Kundig Thomas M.Method of inducing a CTL response
US20020151876 *7 Feb 200217 Oct 2002Tai-Wah ChanDevices and methods for management of bone density
US20020177839 *20 Apr 200228 Nov 2002Cormier Michel J. N.Microprojection array having a beneficial agent containing coating
US20030088204 *2 Nov 20018 May 2003Joshi Ashok VNovel iontophoretic drug delivery systems
US20030088236 *27 Jun 20028 May 2003Johnson Randolph MellusImplantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US20030135202 *17 Jan 200317 Jul 2003Microsolutions, Inc.Implantable osmotic pump
US20040102476 *25 Nov 200227 May 2004Chan Tai WahHigh concentration formulations of opioids and opioid derivatives
US20040157884 *20 Nov 200312 Aug 2004Johnson Randolph MellusDevices and methods for pain management
US20040230183 *18 Feb 200418 Nov 2004Wisam BreegiDrug delivery device and syringe for filling the same
US20040249365 *14 Oct 20039 Dec 2004Microsolutions, Inc.Implantable osmotic pump
US20050070883 *21 Nov 200131 Mar 2005Brown James EDevices and methods for controlled delivery from a drug delivery device
US20050106205 *18 Aug 200419 May 2005Gillis Edward M.Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US20050118246 *29 Oct 20042 Jun 2005Wong Patrick S.Dosage forms and layered deposition processes for fabricating dosage forms
US20050129737 *26 Jan 200516 Jun 2005Johnson Randolph M.Devices and methods for pain management
US20050143789 *25 Feb 200530 Jun 2005Whitehurst Todd K.Methods and systems for stimulating a peripheral nerve to treat chronic pain
US20050154419 *4 Mar 200514 Jul 2005Whitehurst Todd K.Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
US20050187530 *31 May 200125 Aug 2005Davidson Roderick I.Super absorbent driven dispenser
US20050228451 *17 Jun 200513 Oct 2005Jaax Kristen NMethods and systems for treating chronic pelvic pain
US20060020248 *26 Jul 200426 Jan 2006Prescott Anthony DLacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US20060020253 *26 Jul 200426 Jan 2006Prescott Anthony DImplantable device having reservoir with controlled release of medication and method of manufacturing the same
US20060036293 *29 Jul 200516 Feb 2006Whitehurst Todd KMethods for treating gastrointestinal disorders
US20060064140 *7 Oct 200523 Mar 2006Whitehurst Todd KMethods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
US20060129201 *6 Dec 200515 Jun 2006Lee Philip H JStimulation of the stomach in response to sensed parameters to treat obesity
US20060149340 *27 Jan 20066 Jul 2006Karunasiri Rankiri TSystems and methods for providing power to one or more implantable devices
US20060153844 *29 Dec 200513 Jul 2006Thomas KundigMethods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US20060153858 *19 Dec 200513 Jul 2006Kundig Thomas MMethod of inducing a CTL response
US20060161217 *21 Dec 200520 Jul 2006Jaax Kristen NMethods and systems for treating obesity
US20060185665 *22 Feb 200524 Aug 2006Bachinski Thomas JSauna fireplace
US20060194724 *25 Feb 200531 Aug 2006Whitehurst Todd KMethods and systems for nerve regeneration
US20060206165 *21 Oct 200514 Sep 2006Jaax Kristen NOccipital nerve stimulation to treat headaches and other conditions
US20060235484 *25 Oct 200519 Oct 2006Jaax Kristen NStimulation of a stimulation site within the neck or head
US20060247728 *30 Jun 20062 Nov 2006Foster Allison MMethods and systems for treating autism by decreasing neural activity within the brain
US20060264913 *27 Jun 200623 Nov 2006Poutiatine Andrew IImplantable flow regulator with failsafe mode and reserve drug supply
US20070014820 *27 Jun 200618 Jan 2007Dana LitmanovitzOpioid formulations
US20070049988 *30 Dec 20051 Mar 2007Rafael CarbunaruOptimal electrode contact polarity configurations for implantable stimulation systems
US20070066997 *21 Sep 200522 Mar 2007He Tom XMethods and systems for placing an implanted stimulator for stimulating tissue
US20070083240 *7 Dec 200612 Apr 2007Peterson David K LMethods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
US20070100393 *19 Dec 20063 May 2007Whitehurst Todd KTreatment of movement disorders by brain stimulation
US20070112404 *16 Nov 200517 May 2007Mann Alfred EImplantable stimulator
US20070117841 *21 Oct 200424 May 2007Ozes Osman NUse of pirfenidone in therapeutic regimens
US20070156180 *30 Dec 20055 Jul 2007Jaax Kristen NMethods and systems for treating osteoarthritis
US20070219595 *14 Mar 200620 Sep 2007Advanced Bionics CorporationStimulator system with electrode array and the method of making the same
US20070250136 *29 Mar 200625 Oct 2007Karunasiri Rankiri TSystems and methods of facilitating communication between a first and second device
US20080027513 *8 Jul 200531 Jan 2008Advanced Bionics CorporationSystems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
US20080102119 *1 Nov 20061 May 2008Medtronic, Inc.Osmotic pump apparatus and associated methods
US20080131398 *21 Aug 20075 Jun 2008United Therapeutics CorporationCombination therapy for treatment of viral infections
US20080177219 *23 Jan 200724 Jul 2008Joshi Ashok VMethod for Iontophoretic Fluid Delivery
US20080249497 *10 Oct 20079 Oct 2008Wong Patrick S LOsmotically-driven fluid dispenser
US20090035252 *3 May 20065 Feb 2009Kundig Thomas MMethod of inducing a CTL response
US20090192565 *23 Jan 200930 Jul 2009Boston Scientific Neuromodulation CorporationStimulation of the stomach in response to sensed parameters to treat obesity
US20090281605 *21 Jul 200912 Nov 2009Boston Scientific Neuromodulation CorporationEngagement tool for implantable medical devices
US20090304636 *13 Nov 200610 Dec 2009Enterprise Partners Venture CapitalStem Cell Factor Therapy for Tissue Injury
US20100030287 *8 Oct 20094 Feb 2010Boston Scientific Neuromodulation CorporationMethods for treating autism
US20100331807 *31 Aug 201030 Dec 2010Boston Scientific Neuromodulation CorporationTreatment of movement disorders by brain stimulation
US20110009920 *13 Jul 201013 Jan 2011Boston Scientific Neuromodulation CorporationSkull-mounted electrical stimulation system and method for treating patients
US20110029042 *12 Oct 20103 Feb 2011Boston Scientific Neuromodulation CorporationLead assemblies with one or more switching networks
US20110060382 *5 Nov 201010 Mar 2011Boston Scientific Neuromodulation CorporationStimulation of a stimulation site within the neck or head
US20110136847 *17 Sep 20109 Jun 2011Tai Wah ChanHigh Concentration Formulations of Opioids and Opioid Derivatives
US20110172739 *21 Mar 201114 Jul 2011Boston Scientific Neuromodulation CorporationImplantable stimulator
US20110184389 *31 Mar 201128 Jul 2011Medtronic, Inc.Osmotic pump apparatus and associated methods
US20120237353 *22 Sep 201020 Sep 2012Ecp Entwicklungsgesellschaft MbhCompressible rotor for a fluid pump
USRE34365 *5 Aug 199131 Aug 1993 Intravenous system for delivering a beneficial agent
DE2640904A1 *10 Sep 197624 Mar 1977Alza CorpVorrichtung zur abgabe von wirkstoffen durch osmose und verfahren zu deren herstellung
DE2644267A1 *30 Sep 197614 Apr 1977Alza CorpVorrichtung zur abgabe einer fluessigkeit durch osmose
DE3228595A1 *30 Jul 198217 Feb 1983Alza CorpSystem zur parenteralen verabreichung eines wirkstoffs
DE3634864A1 *13 Oct 198614 Apr 1988Alza CorpAbgabevorrichtung zur freisetzung einer auf temperatur ansprechenden masse
EP0048541A1 *30 Jun 198131 Mar 1982Alza CorporationOsmotically driven fluid dispenser
EP0259013A14 Aug 19879 Mar 1988Pharmetrix CorporationPortable controlled release osmotic infusion device
EP1304105A2 *17 Mar 199823 Apr 2003Alza CorporationDiffusional implantable delivery system
EP1304105A3 *17 Mar 199811 Jun 2003Alza CorporationDiffusional implantable delivery system
EP2390262A113 May 200430 Nov 2011Intermune, Inc.Synthetic chemokine receptor ligands and methods of use thereof
EP3025727A130 Sep 20091 Jun 2016The J. David Gladstone InstitutesMethods of treating liver disease
EP3222720A131 Aug 201227 Sep 2017University of Southern CaliforniaMethods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
WO1998043611A1 *17 Mar 19988 Oct 1998Alza CorporationDiffusional implantable delivery system
WO2001026714A112 Oct 200019 Apr 2001Durect CorporationRegulation of drug delivery through flow diversion
WO2002043800A221 Nov 20016 Jun 2002Durect CorporationDevices and methods for controlled delivery from a drug delivery device
WO2004022069A16 Sep 200218 Mar 2004Durect CorporationDelivery of modulators of glutamate-mediated neurotransmission to the inner ear
WO2007059010A213 Nov 200624 May 2007Enterprise Partners Venture CapitalStem cell factor therapy for tissue injury
WO2010107739A216 Mar 201023 Sep 2010The Board Of Trustees Of The Leland Stanford Junior UniversityMethods and compositions of treating a flaviviridae family viral infection
WO2012175698A122 Jun 201227 Dec 2012Université Libre de BruxellesTherapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
WO2013033636A231 Aug 20127 Mar 2013University Of Southern CaliforniaMethods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
WO2015085312A18 Dec 201411 Jun 2015Durect CorporationCompositions comprising antioxidant, fluid dispensers, and methods involving the same
WO2016196840A12 Jun 20168 Dec 2016Principia Biopharma Inc.Tyrosine kinase inhibitors
WO2016210165A123 Jun 201629 Dec 2016Principia Biopharma Inc.Tyrosine kinase inhibitors
WO2017168174A131 Mar 20175 Oct 2017N4 Pharma Uk LimitedNew pharmaceutical forms of sildenafil
Classifications
U.S. Classification222/95, 222/386.5, 222/389, 604/892.1
International ClassificationB01J4/04, A61K9/00, B65D37/00
Cooperative ClassificationB01D61/002, A61K9/0004, B01D61/005
European ClassificationB01D61/00B, B01D61/00B10, A61K9/00L4